Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD8330

Known as: ARRY-424704, ARRY-704, MEK Inhibitor AZD8330 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Dihydropyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.
In human lung cancer, Tripartite motif 65 (TRIM65) is documented as an important regulator in carcinogenesis. Knockdown of TRIM65… Expand
Is this relevant?
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2015
2015
MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation
Conventional high-grade osteosarcoma is the most common primary bone cancer with relatively high incidence in young people… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
[Effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its mechanism].
OBJECTIVE To investigate the effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its… Expand
Is this relevant?
2014
2014
[Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells].
This study was aimed to investigate the effect of MEK inhibitor AZD8330 on proliferation and apoptosis of multiple myeloma IM9… Expand
Is this relevant?
Review
2014
Review
2014
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Mitogen-activated protein kinases (MAPKs) are a family of ubiquitous eukaryotic signal transduction enzymes which link… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2013
2013
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
OBJECTIVE This is the first clinical study of the MEK1/2 inhibitor AZD8330 (ARRY-424704). This phase I study defined the maximum… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
MEK and the inhibitors: from bench to bedside
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2009
2009
Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials
The dual-specificity kinases MEK 1/2 play key roles in tumorgenesis by activating the serine/threonine kinases ERK 1/2. These… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE